Distinct profiles of gastritis in dyspepsia subgroups. Their different clinical responses to gastritis healing after Helicobacter pylori eradication.
BACKGROUND
A contribution of Helicobacter pylori gastritis to the pathogenesis of non-ulcer dyspepsia (NUD) remains uncertain.


METHODS
Administration of an appropriate clinical questionnaire followed by endoscopy allowed us to select, among 139 outpatients with dyspepsia, 87 non-ulcer dyspepsia patients with more severe and group-distinctive symptoms, 35 of whom were classified as having ulcer-like (ULD). 38 as dysmotility-like (DLD), and 14 as reflux-like dyspepsia (RLD). Biopsy specimens were evaluated for H. pylori gastritis in accordance with the Sydney system. The 70 H. pylori-positive cases were treated with omeprazole, 20 mg twice daily, and amoxycillin, 1 g three times daily for 2 weeks.


RESULTS
Higher rates of H. pylori colonization were found histologically in the gastric mucosa of ULD (91%) and RLD (86%) than in that of DLD (68%) or asymptomatic (42%) patients. ULD differed from RLD patients in their higher score of antritis activity. Three and 6 months after H. pylori eradication ULD (but not DLD) showed significant regression of dypspetic symptoms scores.


CONCLUSIONS
It seems likely that H. pylori gastritis, with special reference to active antritis, is among causative factors of ULD. Its role in the pathogenesis of RLD and DLD needs further investigation.
Digestive Physiopathology Unit, IRCCS Policlinico San Matteo, Italy.
E
E
Trespi
F
F
Broglia
L
L
Villani
O
O
Luinetti
R
R
Fiocca
E
E
Solcia
D000328:Adult; D000367:Age Factors; D000658:Amoxicillin / Q000627:therapeutic use*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology; D005260:Female; D005753:Gastric Mucosa / Q000382:microbiology; D005756:Gastritis / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology / Q000503:physiopathology; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000627:therapeutic use*; D015995:Prevalence; D012737:Sex Factors; D013997:Time Factors
D000658:Amoxicillin; D009853:Omeprazole